Cytotoxicity of methotrexate and trimetrexate and its reversal by folinic acid in human leukemic CCRF-CEM cells with carrier-mediated and receptor-mediated folate uptake

Leuk Res. 1989;13(11):981-7. doi: 10.1016/0145-2126(89)90005-2.

Abstract

The cytotoxic effects of the antifolates methotrexate (MTX) and trimetrexate (TMQ) were investigated for two human leukemic CCRF-CEM cell lines, one expressing the "classical" reduced folate/MTX carrier (CEM-RF), another lacking this carrier but expressing a membrane associated folate binding protein (CEM-FBP). CEM-FBP cells were found to be highly resistant to MTX compared to CEM-RF cells, especially in short exposures. For example, after 4 h incubation, IC50 values for MTX were 251 microM and 0.98 microM for CEM-FBP and CEM-RF cells, respectively. On the other hand, CEM-FBP cells were much more sensitive to the lipophilic antifolate TMQ than CEM-RF cells as shown by IC50 values (after 4 h of exposure) of 0.059 microM and 7.5 microM, respectively. Finally, the reversal of TMQ cytotoxicity by folinic acid was significantly impaired for CEM-FBP cells, in contrast to CEM-RF cells. These results indicate that the nature of the membrane transport system for folates can be a critical determinant in tumor cell sensitivity or resistance to antifolates.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biological Transport
  • Carrier Proteins / metabolism
  • Folate Receptors, GPI-Anchored
  • Folic Acid / metabolism*
  • Humans
  • In Vitro Techniques
  • Leucovorin / pharmacology*
  • Leukemia / drug therapy*
  • Leukemia / metabolism
  • Methotrexate / metabolism
  • Methotrexate / toxicity*
  • Quinazolines / metabolism
  • Quinazolines / toxicity*
  • Receptors, Cell Surface*
  • Trimetrexate
  • Tumor Cells, Cultured

Substances

  • Carrier Proteins
  • Folate Receptors, GPI-Anchored
  • Quinazolines
  • Receptors, Cell Surface
  • Folic Acid
  • Leucovorin
  • Trimetrexate
  • Methotrexate